Improvements in Motor and Non-Motor Symptoms of Parkinson’s Disease in Those Treated with Photobiomodulation Plus Exercise: A Sham-Controlled Study
Objective: To assess efficacy of photobiomodulation + exercise to improve Parkinson’s disease (PD) symptoms. The primary outcome measure was timed up-and-go (TUG) and other motor…Correlations of catecholamine metabolites and alpha-synuclein by nigral stimulation in Parkinson’s disease model rat
Objective: We aimed to clarify the effects of substantia nigra (SN) stimulation on catecholamine levels and α-synuclein in PD model rats. Background: Catecholaminergic neurons are…Comparative Analysis of miR-29a Expression in Optimized Medical Therapy and Intestinal Infusion Therapies in Advanced Parkinson’s Disease
Objective: To compare the relative expression of miR-29a in patients with advanced Parkinson's disease (PD) receiving optimized medical therapy (OMT) versus intestinal infusion therapies—levodopa/carbidopa intestinal…Antidepressants Associated with Worsening Dyskinesia in Parkinson’s Disease
Objective: This case report aims to highlight the impact of increasing venlafaxine dose on the worsening of dyskinesias and the onset of ocular dyskinesia³ and…Comparing the Impact of Levodopa versus Pramipexole on Eye-Tracking Parameters in Treatment-Naïve Parkinson’s Disease: A Longitudinal Study
Objective: To investigate the differential effects of levodopa versus pramipexole on eye-tracking parameters in treatment-naïve patients with Parkinson's disease. Background: Parkinson's disease (PD) is characterized…Comparative Safety of Different Routes of Apomorphine Administration in Parkinson’s Disease: A Systematic Review and Meta-Analysis
Objective: To assess the safety profiles of inhaled, sublingual, and subcutaneous apomorphine in patients with Parkinson’s disease (PD). Background: Apomorphine is a direct-acting D1/D2 agonist…Glucagon Like Peptide-1 (GLP-1) Receptor Agonists for Parkinson’s Disease: An Updated Systematic Review and Meta-Analysis
Objective: To evaluate the efficacy and safety of GLP-1 receptor agonists in Parkinson's disease (PD) by adding new 2025 randomized controlled trial (RCT) data, and…Synchronized High Frequency Neural Oscillations as a Biomarker for Differentiating the Internal from the External Segment of the Globus Pallidus in Parkinson’s Disease
Objective: To assess whether using high frequency oscillations (HFO; 150-350 Hz) or beta band oscillations (13-30 Hz) can objectively differentiate the external from the internal…Utilization of Phosphorylated Alpha-Synuclein Skin Biopsy Testing in a Movement Disorders Center
Objective: To describe the utilization patterns of skin biopsy for phosphorylated alpha-synuclein (P-syn) aggregation obtained from three sites (posterior cervical, distal thigh, distal leg) and…Three Biopsies Optimizes Test Performance for the Detection of Cutaneous Phosphorylated Alpha-Synuclein
Objective: To review two independent data sets to define the test performance of skin biopsies for the detection of P-SYN and peripheral nerve degeneration in…
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 436
- Next Page »